The Potential of Synthetic Tumor-Associated Glycoconjugates (S-TAGs) for Generating Monoclonal Antibodies for Breast Cancer Imaging and for Specific Immunotherapy

  • Grant MacLean
  • Alexander McEwan
  • Eleanor Mackie
  • Peter Fung
  • Carina Henningsson
  • Rao Koganty
  • Marian Madej
  • Thomas Sykes
  • Antoine Noujaim
  • Michael Longenecker
Chapter

Abstract

The Thomsen Friedenreich (TF) antigen may be important for the detection and immunotherapy of a number of common cancers including breast cancer. Revealed on normal human erythrocytes by neuraminidase treatment, TF has been characterized as: β-D-Gal-(1–3)- α-GalNAc, attached to glycophorin or other glycoproteins through O-serine or O-threonine linkages (1). Tn, the TF precursor, is reported to be α-GalNAc-O-serine/ threonine. While TF is normally cryptic due to the presence of a terminal sialic acid residue, Tn is exposed in individuals with a recessive genetic disorder (2). Springer (1) has claimed expression of TF and Tn antigens on over 90% of cancers of the breast, lung and pancreas, although the nature of the molecules which bear these antigens and their exact structures has not been defined.

Keywords

Breast Cancer Metastatic Breast Cancer Keyhole Limpet Hemocyanin Active Specific Immunotherapy Thomsen Friedenreich 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G.F. Springer. Science 224: 1198 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    W. Vainchenker, G. Vinci, U. Testa, A. Henri, A. Tabilio, M. Fache, H. Rochant and J. Cartron. J. Clin. Invest. 75: 541 (1985).PubMedCrossRefGoogle Scholar
  3. 3.
    B.M. Longenecker, A.F.R. Rahmann, J. Barrington-Leigh, R.A. Purser, A.H. Greenberg, D.J. Willans, O. Keller, P.K. Petrik, T.Y. Thay, M.R. Suresh and A.A. Noujaim. Int. J. Cancer 33: 123 (1984).PubMedCrossRefGoogle Scholar
  4. 4.
    F.R Rahman and B.M. Longenecker, J. Imrnunol. 129: 2021 (1982).Google Scholar
  5. 5.
    B.M. Longenecker, D.J. Willans, G.D. MacLean, S. Selvaraj, M.R Suresh and A.A. Noujaim. J. Natl. Cancer Inst. 78: 489 (1987).PubMedGoogle Scholar
  6. 6.
    C.M. Henningsson, S. Selvaraj, G.D. MacLean, M.R Suresh, A.A. Noujaim and B.M. Longenecker. Cancer Immunol. Immunother. 25: 231 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    B.M. Longenecker, G.D. MacLean, A.J. McEwan, T. Sykes, C. Henningson, M.R. Suresh, and A.A. Noujaim. In: Altered Glycosylation in Tumor Cells. Alan R. Liss, Inc. UCLA Symposium on Molecular and Cell Biology 79: 307 (1988).Google Scholar
  8. 8.
    J.S. Coon, RS. Weinstein and J.L. Summers. Amer. J. Clin. Pathol. 17: 692 (1982).Google Scholar
  9. 9.
    H. Ohoka, H. Shinomiya, M. Yokoyama, K. Ochi, M. Takeuchi and S. Utsumi. Urol. Res. 13: 47 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    G.F. Springer, P.R Desai, M.S. Marthy, H. Tegetmeyer and E.F. Scanlon. Prog. Allergy 26: 42 (1979).PubMedGoogle Scholar
  11. 11.
    D.R Howard and J.G. Batsakis. Science 210: 201 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    M. Yuan, S.H. Itzkowitz, C.R. Boland, Y.D. Kim, J.T. Tomita, A. Palekar, J.L. Bennington, B.F. Trump and Y.S. Kim. Cancer Res. 46: 4841 (1986) .PubMedGoogle Scholar
  13. 13.
    O. Mäkelä, P. Mattila, N. Rautonen, I. Seppälä, J. Eskola and H. Käyty. J. Immunol. 139: 1999 (1987).PubMedGoogle Scholar
  14. 14.
    W.F. Riesen, F. Skvaril and D.G. Braun. Scand. J. Immunol. 5: 383 (1976).PubMedCrossRefGoogle Scholar
  15. 15.
    D.J. Barrett and E.M. Ayoub. Clin. Exp. Immunol. 63: 127 (1986).PubMedGoogle Scholar
  16. 16.
    R.M. Perlmutter, D. Hansburg, D.E. Briles, R.A. Nicolotti and J.M. Davie. J. Irrmunol. 1221: 566 (1978).Google Scholar
  17. 17.
    C. Moreno and J. Esdaile. Eur. J. Immunol. 13: 262 (1983).PubMedCrossRefGoogle Scholar
  18. 18.
    H.O. Sarvas, L.M. Aaltonen, F. Peterfy and O. Makela. Eur. J. Immunol. 13: 409 (1983).PubMedCrossRefGoogle Scholar
  19. 19.
    L. Hammarstrom, M.A.A. Persson and C.I.E. Smith. Immunology 54: 821 (1985).PubMedGoogle Scholar
  20. 20.
    D.H. Katz and B. Benacerraf. Adv. Immunol. 15: 1 (1972).PubMedCrossRefGoogle Scholar
  21. 21.
    J.G. Howard, G.H. Christie, B.M. Courtenay, E. Leuchars and A.J.S. Davies. Cell Immunol. 2: 64 (1971).CrossRefGoogle Scholar
  22. 22.
    B. Andersson and H. Blomgren. Cell Immunol. 2: 411 (1971).PubMedCrossRefGoogle Scholar
  23. 23.
    W.D. Armstrong, E. Diener and G.R Shellam. J. Exp. Med. 129: 393 (1969).PubMedCrossRefGoogle Scholar
  24. 24.
    P.J. Baker, P.W. Stashak, D.F. Amsbaugh, B. Prescott and RF. Barth. J. Immunol. 105: 1581 (1970).PubMedGoogle Scholar
  25. 25.
    P.J. Baker, N.D. Reed, P.W. Stashak, D.F. Amsbaugh and B. Prescott. J. Exp. Med. 1431 (1973).Google Scholar
  26. 26.
    P.J. Baker, P.W. Stashak, D.F. Amsbaugh and B. Prescott. Immunology 20: 469 (1971).PubMedGoogle Scholar
  27. 27.
    C. Lee. Molecular Immunol. 24: 1005 (1987).CrossRefGoogle Scholar
  28. 28.
    H. Kayhty, J. Eskola, H. Peltola, M.G. Sout, J.S. Samuelson and L.K. Gordon. J. Inf. Dis. 155: 100 (1987).CrossRefGoogle Scholar
  29. 29.
    J.A. Benjamins, RE. Callahan, I.N. Montgomery, D.M. Studzinski and C.A. Dyer. J. Neuroimmunol. 14: 325 (1987).PubMedCrossRefGoogle Scholar
  30. 30.
    T.V. Tittle, A. Mawle and M. Cohn. J. Immunol. 135: 2582 (1985).PubMedGoogle Scholar
  31. 31.
    S. Friberg. J. Natl. Cancer Inst. 48: 1436 (1972).Google Scholar
  32. 32.
    G. Klein. Exp. Cell Res. 2: 518 (1951).CrossRefGoogle Scholar
  33. 33.
    B.H. Sanford, J.F. Codington, RW. Jeanloz and P.D. Palmer. J. Immunol. 110: 1233 (1973).PubMedGoogle Scholar
  34. 34.
    D. Van den Eijden, N.A. Evans, J.F. Codington, V. Reinhold, C. Silber and R.W. Jeanloz. J. Biol. Chem. 254: 12153 (1979).Google Scholar
  35. 35.
    H.G. Rittenhouse. Lab. Med. 16: 556 (1985).Google Scholar
  36. 36.
    C.R Boland, C.K. Montgomery and Y.S. Kim. P.N.A.S. 79: 2051 (1982).PubMedCrossRefGoogle Scholar
  37. 37.
    J.L. Magnini, L. Steplewski, H. Koprowski and V. Ginsburg. Cancer Res. 43: 5489 (1983).Google Scholar
  38. 38.
    M.M. Lippmann, J.M. Venditti, I. Kline and D.L. Elan. Cancer Res. 33: 679 (1973).Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Grant MacLean
    • 1
    • 3
  • Alexander McEwan
    • 2
  • Eleanor Mackie
    • 4
    • 5
  • Peter Fung
    • 4
    • 5
  • Carina Henningsson
    • 4
  • Rao Koganty
    • 5
  • Marian Madej
    • 5
  • Thomas Sykes
    • 5
  • Antoine Noujaim
    • 5
    • 6
  • Michael Longenecker
    • 4
    • 5
  1. 1.Departments of MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Departments of Nuclear MedicineUniversity of AlbertaEdmontonCanada
  3. 3.Cross Cancer Institute Departments of MedicineUniversity of AlbertaEdmontonCanada
  4. 4.Departments of ImmunologyUniversity of AlbertaEdmontonCanada
  5. 5.Faculty of Medicine, and Faculty of PharmacyUniversity of AlbertaEdmontonCanada
  6. 6.Biomira Inc.EdmontonCanada

Personalised recommendations